Title

The Effects of Soy Isoflavones to Improve the Metabolism of Glucose and Lipids
The Study of the Effects of Soy Isoflavones on the Metabolism of Glucose and Lipids in Postmenopausal Chinese Women With Impaired Glucose Regulation
  • Phase

    N/A
  • Study Type

    Interventional
  • Study Participants

    165
Many studies showed that soy foods or soy isoflavones can lower the risk of cardiovascular disease (CVD), osteoporosis and some cancers, but few human studies assessed effects of purified isoflavone components (genistein and daidzein) on glucose metabolism. This double-blinded, randomized, placebo-controlled trial will examine the effects of purified genistein and daidzein on glucose metabolism in prediabetic or diabetic women. One hundred and eighty eligible women age 30-70 years(without any treatment of diabetic drugs) will be recruited and randomly allocated into the following three arms: Placebo (10g isolated soy protein, ISP); Genistein (10g ISP + 50mg genistein); Daidzein (10g ISP + 50mg daidzein) per day for 6 mo. Fasting glucose, lipids, insulin, inflammation marks and post-load for glucose and insulin will be determined at 0, 3th, and 6th month. Changes in these indices will be compared among the three groups.
Subjects were Chinese adult women, age 30-70 year, with an FG concentration ranging from 5.6 to 7.0 mmol/L or 2-h PG concentration ranging from 7.8-11.0 mmol/L or with newly diagnosed diabetes not requiring medication treatment according to a doctor's suggestion or participants did not willing to take medication themselves, and managed their diabetes just with a stable diet and exercise. Women were excluded if they had a history of coronary heart disease, stoke, thyroid disease, severe liver, lung, or gastrointestinal tract diseases; were currently or in the past 8 weeks used hypoglycemic or lipid-lowering or weight-reduction agents; were occurrence of diabetic complications; use of hormone replacement therapy; allergy to soy;were long-term antibiotics users.
Study Started
Aug 31
2009
Primary Completion
Jun 30
2011
Study Completion
Sep 30
2011
Results Posted
Oct 16
2012
Estimate
Last Update
Oct 17
2012
Estimate

Dietary Supplement Placebo

10g soy protein isolated per day

Dietary Supplement Daidzein

50mg daidzein +10g soy protein isolated per day

Dietary Supplement Genistein

50mg genistein +10g soy protein isolated per day

Placebo Placebo Comparator

10g soy protein isolated powder patch by mouth everyday for 6months

Daidzein Experimental

10g soy protein isolated plus 50mg daidzein powder patch by mouth everyday for 6 months

Genistein Experimental

10g soy protein isolated plus 50mg genistein powder patch by mouth everyday for 6 months

Criteria

Inclusion Criteria:

Chinese women aged 30-70 y
Fasting glucose >=5.6 mmol/l; post-load glucose >=7.8 mmol/l

Exclusion Criteria:

Diabetes renal diseases
Confirmed CVD, chronic liver,kidney diseases,Thyroid disease
Medications affecting glucose or lipid metabolism

Summary

Placebo

Daidzein

Genistein

All Events

Event Type Organ System Event Term Placebo Daidzein Genistein

Percentage Change in Fasting Plasma Glucose

(6th month value-baseline value)/baseline value*100%

Placebo Group

-1.8
percentage of change (Mean)
Standard Deviation: 13.5

Daidzein Group

-1.0
percentage of change (Mean)
Standard Deviation: 12.61

Geinstein Group

-4.89
percentage of change (Mean)
Standard Deviation: 11.79

Percentage Change in 120-minutes Postload Plasma Glucose

(6th month value-baseline value)/baseline*100%

Placebo Group

-4.9
percentage of change (Mean)
Standard Deviation: 20.67

Daidzein Group

-3.13
percentage of change (Mean)
Standard Deviation: 20.60

Geinstein Group

-5.59
percentage of change (Mean)
Standard Deviation: 24.23

Percentage Change in HbA1C

(6th month value-baseline value)/baseline value*100%

Placebo Group

-1.38
percentage of change (Mean)
Standard Deviation: 7.17

Daidzein Group

-1.37
percentage of change (Mean)
Standard Deviation: 5.99

Geinstein Group

-1.3
percentage of change (Mean)
Standard Deviation: 9.29

Percentage Change in AUC of Glucose

values were from 75g glucose oral glucose tolerance test and caculated as (6th month value-baseline value)/baseline value*100%

Placebo Group

-6.23
percentage of change (Mean)
Standard Deviation: 14.06

Daidzein Group

-3.27
percentage of change (Mean)
Standard Deviation: 16.98

Geinstein Group

-5.24
percentage of change (Mean)
Standard Deviation: 17.96

Percentage Change in Fasting Plasma Insulin

(6th month value-baseline value)/baseline value*100%

Placebo Group

25.27
percentage of change (Mean)
Standard Deviation: 114.23

Daidzein Group

21.41
percentage of change (Mean)
Standard Deviation: 91.23

Geinstein Group

6.06
percentage of change (Mean)
Standard Deviation: 78.26

Percentage Change in HOMA-IR

HOMA-IR was calculated with the homeostasis model assessment for insulin resistance,and it is caculated as the following equation: HOMA-IR=FIns×FG/22.5, where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter. The percentage change was caculated as (6th month value-baseline value)/baseline value*100%

Placebo Group

22.83
Percentage of change (Mean)
Standard Deviation: 107.41

Daidzein Group

21.6
Percentage of change (Mean)
Standard Deviation: 98.88

Geinstein Group

-0.22
Percentage of change (Mean)
Standard Deviation: 64.03

Percentage Change in QUICKI

QUICKI is the abbreviation of Quantitative Insulin Sensitivity Check Index,and it is a marker to evaluate insulin sensitivity in HOMA model.It is calculated by using the following equation: 1/(logFIns +logFG),where FIns represents fasting insulin in microunits per milliliter, and FG is in millimoles per liter. The percentage change was caculated as (6th month value-baseline value)/baseline value*100%

Placebo Group

2.32
Percentage of change (Mean)
Standard Deviation: 19.47

Daidzein Group

0.18
Percentage of change (Mean)
Standard Deviation: 15.60

Geinstein Group

6.29
Percentage of change (Mean)
Standard Deviation: 17.77

Percentage Change in Total Cholesterol

(6th month value-baseline value)/baseline value*100%

Placebo Group

2.85
Percentage of change (Mean)
Standard Deviation: 40.06

Daidzein Group

-0.59
Percentage of change (Mean)
Standard Deviation: 11.90

Geinstein Group

-0.64
Percentage of change (Mean)
Standard Deviation: 15.83

Percentage Change in Triglyceride

(6th month value-baseline value)/baseline value*100%

Placebo Group

5.93
Percentage of change (Mean)
Standard Deviation: 45.50

Daidzein Group

3.43
Percentage of change (Mean)
Standard Deviation: 38.90

Geinstein Group

-1.56
Percentage of change (Mean)
Standard Deviation: 39.15

Percentage Change in High Density Lipoprotein Cholesterol

(6th month value-baseline value)/baseline value*100%

Placebo Group

3.18
Percentage of change (Mean)
Standard Deviation: 20.40

Daidzein Group

1.36
Percentage of change (Mean)
Standard Deviation: 15.21

Geinstein Group

2.15
Percentage of change (Mean)
Standard Deviation: 14.54

Percentage Change in Low Density Lipoprotein Cholesterol

(6th month value-baseline value)/baseline value*100%

Placebo Group

1.08
Percentage of change (Mean)
Standard Deviation: 24.46

Daidzein Group

-0.93
Percentage of change (Mean)
Standard Deviation: 21.21

Geinstein Group

1.86
Percentage of change (Mean)
Standard Deviation: 19.39

Total Urinary Isoflavones

Placebo Group

8.538
ug/ml (Geometric Mean)
Standard Deviation: 10.153

Daidzein Group

25.818
ug/ml (Geometric Mean)
Standard Deviation: 31.780

Geinstein Group

15.467
ug/ml (Geometric Mean)
Standard Deviation: 22.022

Urinary Daidzein

Urinary daidzein excretion

Placebo Group

3.34
ug/ml (Geometric Mean)
Standard Deviation: 4.81

Daidzein Group

11.8
ug/ml (Geometric Mean)
Standard Deviation: 11.14

Geinstein Group

3.73
ug/ml (Geometric Mean)
Standard Deviation: 8.83

Urinary Genistein

Urinary genistein excretion

Placebo Group

1.32
ug/ml (Geometric Mean)
Standard Deviation: 1.72

Daidzein Group

1.89
ug/ml (Geometric Mean)
Standard Deviation: 2.59

Geinstein Group

6.54
ug/ml (Geometric Mean)
Standard Deviation: 8.97

Total Energy Intake at Follow-up

The energy intake was evaluated by 3 days dietary records.

Placebo Group

1575.0
kcal (Mean)
Standard Deviation: 575

Daidzein Group

1473.0
kcal (Mean)
Standard Deviation: 294

Geinstein Group

1579.0
kcal (Mean)
Standard Deviation: 367

Total

165
Participants

Age Continuous

56.57
years (Mean)
Standard Deviation: 10.17

Age, Categorical

Region of Enrollment

Sex: Female, Male

Overall Study

Placebo

Daidzein

Genistein

Drop/Withdrawal Reasons

Placebo

Daidzein

Genistein